Physician profile
James D Wolfe
NPI 1194733428
$178,361.29
in general payments reported to CMS, 2019-2025
33 companies · $1,752 in 2025
The $1,752 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,479 · 2020: $1,023 · 2021: $917 · 2022: $944 · 2023: $1,020 · 2024: $171K · 2025: $1,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $170K · Food and Beverage: $3,491 · Travel and Lodging: $239 · Education: $30.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $170,237.48 |
| Food and Beverage | $3,491.31 |
| Travel and Lodging | $238.75 |
| Education | $30.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $170,237.48 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $3,248.27 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,981.57 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $449.19 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $348.83 | 2019-2025 | Dupixent |
| Genzyme Corporation | $341.41 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $212.13 | 2025 | Neffy |
| Alk-Abello, INC | $206.44 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $158.32 | 2019-2022 | |
| Optinose US, INC. | $154.68 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.70 | 2019-2022 | |
| Mylan Specialty L.P. | $113.62 | 2019-2024 | Yupelri |
| Pfizer INC. | $84.74 | 2019-2025 | |
| Shire North American Group INC | $83.87 | 2019 | |
| Csl Behring | $78.74 | 2022-2025 | Hizentra, Andembry |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $73.39 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $72.24 | 2023-2024 | Ryaltris |
| Merck Sharp & Dohme LLC | $65.73 | 2023 | |
| Kaleo, INC. | $59.91 | 2019-2021 | |
| Philips North America LLC | $37.76 | 2024 | (8874) Incourage |
| Paratek Pharmaceuticals, INC. | $29.37 | 2025 | Xhance |
| Grifols USA, LLC | $28.32 | 2025 | Xembify |
| Leo Pharma INC. | $26.49 | 2024 | Adbry |
| Advanced Respiratory, INC | $25.19 | 2020 | |
| Lilly USA, LLC | $24.20 | 2024 | Ebglyss |
| Genentech USA, INC. | $22.32 | 2019 | |
| Viatris Specialty LLC | $21.27 | 2025 | Yupelri |
| Ionis Pharmaceuticals, INC. | $19.70 | 2025 | Dawnzera |
| Amgen INC. | $15.41 | 2025 | Tezspire |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.